Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension
Information source: University Health Network, Toronto
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension, Pulmonary
Intervention: Sildenafil (Drug)
Phase: Phase 3
Status: Withdrawn
Sponsored by: University Health Network, Toronto
Summary
This study will examine the effects of add-on sildenafil to bosentan monotherapy in patients
with Pulmonary Arterial Hypertension. Patients on bosentan monotherapy will be followed
every 6 months to assess if they have met the pre-defined treatment goals. If a patient
fails to achieve these treatment goals or fails to maintain them, sildenafil will be added
to their existing bosentan monotherapy. Patients will be assessed 6 months after start of
combination therapy for changes in 6MWT, Borg dyspnea scale, WHO functional class, quality
of life.
Clinical Details
Official title: Addition of Sildenafil to Bosentan Monotherapy in Patients With Pulmonary Arterial Hypertension (PAH)
Study design: N/A
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion & Exclusion Criteria
Locations and Contacts
Additional Information
Last updated: November 12, 2009
|